Shocks from pacemaker cardioverter defibrillators increase with amiodarone in patients at high risk for sudden cardiac death

Abhijit A. Shinde, Elizabeth B. Juneman, Brian Mitchell, Mary K. Pierce, Mohamed A. Gaballa, Steven Goldman, Hoang Thai

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

The efficacy of amiodarone used in combination with a pacemaker cardioverter defibrillator (PCD) to decrease episodes of ventricular tachycardia and subsequent PCD shocks is not clear. We examined a retrospective registry of 82 patients with PCD implantation to define the efficacy of amiodarone treatment. We compared patients treated with amiodarone (for 24 consecutive months without interruption) versus no amiodarone. In patients treated with amiodarone there was a 3-fold increase (p = 0.02) in PCD shocks; in patients not on beta-blockers, amiodarone resulted in a 6-fold increase (p<0.05) in PCD shocks. Patients with a left ventricular ejection fraction >30% on amiodarone and patients <72 years old had increases (p<0.05) in PCD shocks. In conclusion, patients treated with amiodarone had more PCD shocks than those not treated. These findings are unexpected and merit a prospective study.

Original languageEnglish (US)
Pages (from-to)143-148
Number of pages6
JournalCardiology
Volume100
Issue number3
DOIs
StatePublished - Dec 8 2003

Keywords

  • Amiodarone
  • Pacemaker (internal) cardioverter defibrillator

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Shocks from pacemaker cardioverter defibrillators increase with amiodarone in patients at high risk for sudden cardiac death'. Together they form a unique fingerprint.

  • Cite this